公开(公告)号：US20100143457A1

公开(公告)日：2010-06-10

申请号：US12653245

申请日：2009-12-09

申请人： Ge Wei ,  Krishnasamy Panneer Selvam ,  Louis Bookbinder ,  Gregory I. Frost

发明人： Ge Wei ,  Krishnasamy Panneer Selvam ,  Louis Bookbinder ,  Gregory I. Frost

IPC分类号： A61K38/47 ,  C12N9/26 ,  C12N9/96 ,  C07H21/04 ,  C12N15/63 ,  C12N5/10 ,  A61K39/395 ,  A61K9/127 ,  A61K38/20 ,  A61K38/21 ,  A61P35/00

CPC分类号： C12N9/2408 ,  A61K38/00 ,  A61K47/60 ,  A61K47/61 ,  A61K47/6435 ,  C12N9/2474

摘要： Soluble PH20 polypeptides are provided, including extended soluble PH20 polypeptides, and uses thereof. Also provided are other C-terminally truncated PH20 polypeptides and partially deglycosylated PH20 polypeptides and uses thereof.

摘要翻译： 提供可溶性PH20多肽，包括延长的可溶性PH20多肽及其应用。 还提供了其它C末端截短的PH20多肽和部分去糖基化的PH20多肽及其用途。

公开(公告)号：US20100022455A1

公开(公告)日：2010-01-28

申请号：US12493912

申请日：2009-06-29

申请人： Ashutosh CHILKOTI

发明人： Ashutosh CHILKOTI

IPC分类号： A61K38/26 ,  A61K38/00 ,  A61K38/22 ,  C07K2/00 ,  C07H21/00 ,  C12N15/63 ,  C12N1/21 ,  A61P3/10 ,  A61K38/28 ,  A61K38/36

CPC分类号： A61K38/28 ,  A61K38/16 ,  A61K38/2278 ,  A61K38/26 ,  A61K38/4846 ,  A61K45/06 ,  A61K47/6435 ,  A61K47/65 ,  C07K14/575 ,  C07K14/605 ,  C07K14/78 ,  C07K19/00 ,  C07K2319/31

摘要： The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.

摘要翻译： 本发明提供治疗剂和包含弹性蛋白样肽（ELP）和治疗性蛋白质的组合物。 在一些实施方案中，治疗性蛋白质是GLP-1受体激动剂，胰岛素或因子VII / VIIa，包括功能类似物。 本发明还提供编码多核苷酸，以及制备和使用治疗剂的方法。 治疗剂与其作为治疗剂的用途有关，其中尤其包括身体的半衰期，清除和/或持久性中的一种或多种，​​溶解度和生物利用度。

公开(公告)号：US20090197316A1

公开(公告)日：2009-08-06

申请号：US12373176

申请日：2007-07-13

申请人： Richard Alan Johnson ,  John Rodney Woodrow

发明人： Richard Alan Johnson ,  John Rodney Woodrow

IPC分类号： C12N9/98 ,  C07K1/10

CPC分类号： C07K1/02 ,  A61K9/1658 ,  A61K9/5169 ,  A61K47/64 ,  A61K47/643 ,  A61K47/6435 ,  A61K47/644 ,  A61K47/6929 ,  A61K49/0485 ,  A61K49/085 ,  A61K49/143 ,  A61K49/1881 ,  A61K51/081 ,  A61K51/1255 ,  B82Y5/00 ,  C07K1/08 ,  C07K1/10

摘要： Protein particles are prepared by causing or allowing protein molecules dispersed in a liquid medium at a concentration of 8 mg.mL-1 or greater to react in the presence of a zero-length crosslinker, so as to produce protein particles comprising protein molecules that are covalently bonded together. The protein particles may be produced with sizes in the sub-micron range with closely defined sizes and size distributions. The particles have applications in many fields, but are useful inter alia for the delivery of therapeutic agents and other agents, eg imaging contrast agents, to the body.

摘要翻译： 通过使分散在8mg.mL-1或更高浓度的液体培养基中的蛋白质分子在零长度交联剂的存在下反应来制备蛋白质颗粒，以产生包含蛋白质分子的蛋白质颗粒， 共价键合。 蛋白质颗粒可以以亚微米范围内的尺寸制造，具有紧密限定的尺寸和尺寸分布。 这些颗粒在许多领域中具有应用，但是尤其可用于将治疗剂和其它试剂（例如成像造影剂）递送至身体。

公开(公告)号：US20090004104A1

公开(公告)日：2009-01-01

申请号：US12158190

申请日：2006-12-20

申请人： Ashutosh Chilkoti

发明人： Ashutosh Chilkoti

IPC分类号： A61K51/08 ,  A61K47/48 ,  A61K49/00 ,  A61K38/21 ,  A61K39/44 ,  A61K38/16 ,  A61K31/70 ,  A61K31/711 ,  A61K31/704 ,  A61K31/337 ,  A61K33/24 ,  A61K31/075 ,  A61K103/34 ,  A61K31/7105

CPC分类号： C07K14/78 ,  A61K38/193 ,  A61K38/21 ,  A61K47/6435 ,  A61K49/085 ,  A61K49/14 ,  C07K2319/00

摘要： Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP.

摘要翻译： 本文提供增强活性剂的体内功效的方法，其包括：向受试者施用与生物弹性聚合物或弹性蛋白样肽偶联的活性剂，其中活性剂的体内功效与 当向受试者施用不与生物弹性聚合物或ELP（或不结合）生物弹性聚合物或ELP时相同的活性剂。

公开(公告)号：US20060233854A1

公开(公告)日：2006-10-19

申请号：US11472437

申请日：2006-06-22

申请人： Dror Seliktar ,  Liora Almany

发明人： Dror Seliktar ,  Liora Almany

IPC分类号： A61F13/00 ,  A61K38/18 ,  A61K38/21 ,  A61K38/48

CPC分类号： A61L27/225 ,  A61K38/363 ,  A61K38/39 ,  A61K38/45 ,  A61K47/60 ,  A61K47/6435 ,  A61K47/6903 ,  A61L27/18 ,  A61L27/227 ,  A61L27/24 ,  A61L27/26 ,  A61L27/38 ,  A61L27/52 ,  A61L27/54 ,  A61L27/58 ,  A61L2300/414 ,  A61L2300/418 ,  A61L2430/02 ,  A61L2430/06 ,  A61L2430/34 ,  C12M25/14 ,  C12N5/0068 ,  C12N2533/30 ,  C12N2533/40 ,  C12N2533/50 ,  C12N2533/52 ,  C12N2533/54 ,  C12Y203/02013 ,  C08L71/02

摘要： The present invention relates to biodegradable scaffolds composed of a naturally-occurring protein backbone cross-linked by a synthetic polymer. Specifically, the present invention provides PEGylated-fibrinogen scaffold and methods of generating and using same for treating disorders requiring tissue regeneration.

摘要翻译： 本发明涉及由合成聚合物交联的天然存在的蛋白质骨架组成的生物可降解支架。 具体而言，本发明提供了聚乙二醇化纤维蛋白原骨架及其生产和使用它们来治疗需要组织再生的疾病的方法。

公开(公告)号：US07101557B2

公开(公告)日：2006-09-05

申请号：US10375741

申请日：2003-02-27

申请人： Philip E. Thorpe ,  Steven W. King ,  Boning Gao

发明人： Philip E. Thorpe ,  Steven W. King ,  Boning Gao

IPC分类号： A61K39/00 ,  A61K39/40 ,  A61K39/395 ,  A01N25/00 ,  C07K1/00

CPC分类号： A61K47/6813 ,  A61K47/6435 ,  Y10S514/834 ,  Y10S530/827 ,  Y10S530/829

摘要： The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulant-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVIIa activators.

公开(公告)号：US07091175B2

公开(公告)日：2006-08-15

申请号：US10491418

申请日：2002-10-02

申请人： Kiyoshi Nokihara ,  Yoshinosuke Hamada ,  Nariaki Matsuura ,  Junzo Takahashi

发明人： Kiyoshi Nokihara ,  Yoshinosuke Hamada ,  Nariaki Matsuura ,  Junzo Takahashi

IPC分类号： A01N37/18

CPC分类号： C07K7/06 ,  A61K38/08 ,  A61K47/6435 ,  A61L27/22 ,  A61L27/24 ,  A61L27/34 ,  C07K5/0806 ,  C07K5/081 ,  C07K5/1013 ,  C07K5/1016

摘要： A novel angiogenesis drug which can be clinically used for therapies of human or the like is disclosed. The angiogenesis drug according to the present invention comprises a peptide as an effective component, which has a prescribed amino acid sequence and has an angiogenesis action.

摘要翻译： 公开了可以临床上用于人类等的治疗的新型血管生成药物。 根据本发明的血管发生药物包含具有规定的氨基酸序列并具有血管生成作用的作为有效成分的肽。

公开(公告)号：US20040266696A1

公开(公告)日：2004-12-30

申请号：US10491418

申请日：2004-06-01

发明人： Kiyoshi Nokihara ,  Yoshinosuke Hamada ,  Nariaki Matsuura ,  Junzo Takahashi

IPC分类号： A61K038/08

CPC分类号： C07K7/06 ,  A61K38/08 ,  A61K47/6435 ,  A61L27/22 ,  A61L27/24 ,  A61L27/34 ,  C07K5/0806 ,  C07K5/081 ,  C07K5/1013 ,  C07K5/1016

摘要： A novel angiogenesis drug which can be clinically used for therapies of human or the like is disclosed. The angiogenesis drug according to the present invention comprises a peptide as an effective component, which has a prescribed amino acid sequence and has an angiogenesis action.

公开(公告)号：US06713453B2

公开(公告)日：2004-03-30

申请号：US09963156

申请日：2001-09-25

申请人： Heinz Redl ,  Walter Fuerst ,  Rudolf Kneidinger ,  Sam L. Helgerson ,  Douglas Looker ,  Elisabeth M. Inman ,  Jane P. Richards ,  Catalina Wong

发明人： Heinz Redl ,  Walter Fuerst ,  Rudolf Kneidinger ,  Sam L. Helgerson ,  Douglas Looker ,  Elisabeth M. Inman ,  Jane P. Richards ,  Catalina Wong

IPC分类号： A61K3818

CPC分类号： C07K14/745 ,  A61K38/00 ,  A61K47/64 ,  A61K47/6435 ,  A61K47/665 ,  B82Y5/00

摘要： A fibrin/fibrinogen binding conjugate for forming a depot for the sustained release of a pharmaceutically active substance from a fibrin clot. The conjugate comprises a fibrin/fibrinogen binding moiety bound to a pharmaceutically active substance either directly or via an intervening substance capturing moiety such as an antibody. The conjugate can also be a recombinant fusion protein comprising a fibrin/fibrinogen binding moiety such as VEGF165 C-terminal domain fused to a wound-healing substance such as leptin.

公开(公告)号：US20240277858A1

公开(公告)日：2024-08-22

申请号：US18174751

申请日：2023-02-27

申请人： Aro Biotherapeutics Company

发明人： Russell C. Addis ,  Zhanna Druzina ,  Robert Kolakowski ,  Swapnil Kulkarni ,  Steven G. Nadler ,  Karyn O'Neil ,  Yao Xin

IPC分类号： A61K47/64 ,  A61K31/7088 ,  C07K14/435 ,  C12N15/113

CPC分类号： A61K47/6435 ,  A61K31/7088 ,  C07K14/435 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/3513 ,  C12N2320/32

摘要： The present disclosure relates to polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the same.